Tempest Therapeutics Inc. (NASDAQ:TPST) saw its stock rise significantly on Thursday, owing to a notable increase in trading volume, exceeding 23 million shares. This surge is primarily linked to the company’s recent collaboration with Roche Holdings AG (OTC:RHHBY) aimed at advancing the clinical evaluation of amezalpat (TPST-1120). The agreement is focused on progressing amezalpat in...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here